Takeout of RayThera Expands Biogen's Presence in I&I

Research evidence excerpt

Takeout of RayThera Expands Biogen's Presence in I&I

Information may be available to BMO Capital Markets or its affiliates that is not reflected in this report. The information in this report is not

intended to be used as the primary basis of investment decisions, and because of individual client objectives, should not be construed as advice

designed to meet the particular investment needs of any investor. The information in this report is based on general considerations and do not

purport to meet the objectives or needs of specific recipients. Nothing herein constitutes any investment, legal, tax or other advice nor is it to be

relied on in any investment or decision. If you are in doubt about any of the contents of this document, the reader should obtain independent

professional advice. This material is for information purposes only and is not an offer to sell or the solicitation of an offer to buy any security.

In furnishing this report, BMO Capital Markets intends to take advantage of the exemption from the principal and agency trading restrictions

in Section 206(3) of the Investment Advisers Act of 1940 and Rule 206(3)-1 thereunder. Accordingly, recipients of this report are advised that

BMO Capital Markets or its affiliates may act as principal for its own account or agent for another person in connection with the purchase or sale

of any security mentioned in or the subject of this report. BMO Capital Markets or its affiliates, officers, directors or employees have a long or

short position in many of the securities discussed herein, related securities or in options, futures or other derivative instruments based thereon.

The reader should assume that BMO Capital Markets or its affiliates may have a conflict of interest and should not rely solely on this report in